Poorya Fazel, MD
Interventional Cardiology · Tulsa, OKNPI 1790993483
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Boston Scientific at 33.9% of the total.
Across 213 payments — averaging $136.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Shockwave Medical, Inc$8K
- Medtronic$3K
- Abbott$2K
- Edwards Lifesciences$2K
- Abiomed$1K
- plus $4K from 23 others
Across 1 payment — averaging $6975.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$7K
What the payments were for
- Consulting fees$5,84420%
- Speaking & faculty fees$6,60023%
- Travel & lodging$4,24415%
- Food & beverage$12,38143%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 72 | $9,867 |
| Shockwave Medical, Inc | 14 | $7,996 |
| Medtronic(2 entities) | 21 | $2,597 |
| Abbott | 19 | $2,011 |
| Edwards Lifesciences | 15 | $1,765 |
| Abiomed | 20 | $1,324 |
| Philips North America LLC | 5 | $1,260 |
| Inari Medical, Inc. | 13 | $707 |
| Penumbra, Inc. | 4 | $554 |
| Stryker | 3 | $238 |
| Impulse Dynamics (USA) Inc. | 1 | $148 |
| Amgen | 5 | $95 |
| Silk Road Medical, Inc. | 2 | $89 |
| Angiodynamics, Inc. | 2 | $69 |
| Cvrx, Inc. | 1 | $46 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $42 |
| Atricure, Inc. | 1 | $38 |
| W. L. Gore & Associates, Inc. | 2 | $30 |
| AstraZeneca | 1 | $25 |
| Cook Medical LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $18 |
| Novo Nordisk | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Asahi Intecc USA, Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$7,565
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$7,226
- COREVALVE EVOLUT R$1,531
- (9520) IGT Devices Undivided$951
- Impella$821
- TRICLIP$676
- Vascular Lithotripsy$584
- FLOWTRIEVER CATHETER, S$562
- CoreValve Evolut$499
- Indigo System$416
- Watchman$344
- CT THROMBECTOMY SYSTEM KIT$332
- MitraClip$297
- OPTIMIZER$295
- GENERAL - STRUCTURAL HEART$247
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$202
- SAPIEN 3 Ultra RESILIA$198
- Confirm Rx$175
- NAVITOR$170
- AMPLATZER AMULET$165
How this compares
$29,076 in reported general payments places this provider in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 401 | $442,129 |
| XareltoRivaroxaban | 138 | $153,654 |
| EntrestoSacubitril/Valsartan | 59 | $63,673 |
| Repatha SureclickEvolocumab | 61 | $59,406 |
| BrilintaTicagrelor | 33 | $21,723 |
| Atorvastatin Calcium | 482 | $12,355 |
| Praluent PenAlirocumab | 17 | $11,911 |
| Rosuvastatin Calcium | 270 | $8,513 |
| Metoprolol Succinate | 330 | $6,863 |
| ClopidogrelClopidogrel Bisulfate | 318 | $6,499 |
| Ezetimibe | 115 | $5,244 |
| VascepaIcosapent Ethyl | 16 | $4,957 |
| Carvedilol | 362 | $4,201 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $3,443 |
| Losartan Potassium | 210 | $3,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $12 | $63,67359 claims |
| AstraZenecaBrilinta | $25 | $21,72333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.